A premium of 43%! Pfizer (PFE.US) will throw 4.9 billion to acquire Metsera (MTSR.US), doubling down on the weight loss drug market.

Financial Channel App learned that Pfizer (PFE.US) has agreed to acquire the obesity drug research start-up company Metsera (MTSR.US) for an enterprise value of about $4.9 billion, aiming to strengthen its research and development pipeline. Earlier, the company faced setbacks in the development of a key weight loss drug.